Equity
€20,460 from €126,661 in 2018
Equity fell by 84% in 7 years.
MEDOCULUS
Lifetime
10 annual accounts with figures on one time axispeak €381,845 (2025)
€381,845▲ 1.6%
lowest -€2,997 (2017)
€165,281▼ 9.4%
peak €126,661 (2018)
€20,460unchanged
€792,041▼ 4.9%
peak 1 FTE (2020)
-not published
Board2 names since 2016
2 directors and 1 other
Documentsfilings and deeds
18-08-202618 days late
2025micro format
Dividend €165,281
Key points
from the 2025 annual accountsDebts
€792,041 97% of the balance sheet
Financial debts 47%Suppliers 0%Taxes and wages 4%Other 49%
Of this, €421,602 falls due within a year.
Position in the sector
2.5%
Lower solvency than 92% of companies in human health. Sector median 63.1% · 21,322 companies.
2025 accounts filed 18 days after the deadline
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 1,325 companies had the same profile as MEDOCULUS has now. Each dot stands for 4 companies, two years later.
95.2%
were still trading
3.2%
stopped another way
1.4%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,325 companies, not a prediction for MEDOCULUS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 15-11-2023
Manager
- 100 sharesdeed of 13-09-2016
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0661897712
Appointment: (director)
“De vennootschap heeft tot voorwerp de uitoefening in België en in de overige landen van de Europese Unie, van…” (deed in Dutch) · General meeting of 15-11-2023 · Gazette deed
Publication in the Belgian Official Gazette
Gazette deed
First establishment
Hovestraat 89, Edegem
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MEDOCULUS Edegem | €812,501 | €381,845 | 2.5% | - |
| Dries De Cock M.D. Ypres | €796,252 | €367,178 | 2.6% | - |
| WERBROUCK B MD Ypres | €854,960 | €420,747 | 26.5% | - |
| LUMINE GROUP Oud-Heverlee | €933,640 | €410,770 | 38.3% | - |
| DR. VERBEEK SANNE, Pathologische Anatomie Geel | €776,333 | €426,688 | 40.9% | - |
| Heuppraktijk Westerlo | €826,806 | €415,214 | 7.4% | - |
| DR. TOMAS DE KEYZER Beerse | €690,238 | €364,196 | 2.7% | - |
These companies have the same main activity as MEDOCULUS: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €690,000 and €934,000, founded between 2013 and 2018.
Official details
Source: KBO- Status
- Active since 22-08-2016Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Joint committee
- 330.04Health institutions and services · annual accounts 2025
- Establishment unit
- 2.256.205.9442650 Edegem, since 01-09-2016
- Financial year end
- 31 December
- Peppol
- Reachable since 27-03-2025
Annual accounts 2025
- ≈ €570,000estimated
- €812,501▼ 4.8%
- Employeeson 31-12-2025
- 2=
- Filing
- Filed on 18-08-2026
Insights on MEDOCULUS
MEDOCULUS files the micro format. That format states no turnover. The gross margin rose from €133,409 in 2016 to €381,845 in 2025.
The balance sheet grew most from 2017 to 2018 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MEDOCULUS
- What is the company number of MEDOCULUS?
- The company number of MEDOCULUS is 0661.897.712. The VAT number is the same number with BE in front: BE 0661.897.712.
- Where is MEDOCULUS based?
- The registered office is at Molenlei 205, 2650 Edegem.Company details
- What does MEDOCULUS do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of MEDOCULUS?
- MEDOCULUS is a private limited company (BV).
- When was MEDOCULUS founded?
- MEDOCULUS was founded on 22-08-2016.
- Is MEDOCULUS still active?
- Yes, MEDOCULUS is an active enterprise in the KBO register.
- How many employees does MEDOCULUS have?
- MEDOCULUS had an average of 2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does MEDOCULUS fall under?
- In its 2025 annual accounts, MEDOCULUS states joint committee 330.04 (Health institutions and services).
- What is the turnover of MEDOCULUS?
- The turnover in financial year 2025 is ≈ €570,000. This figure is estimated from the gross margin of €381,845 and 31 comparable companies (NACE 86220). It probably lies between €510,000 and €800,000.
- Is MEDOCULUS profitable?
- In financial year 2025, MEDOCULUS made a profit of €165,281.
- Where can I find the annual accounts of MEDOCULUS?
- MEDOCULUS filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MEDOCULUS due?
- MEDOCULUS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.